Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov135810.25208/vdv1358REVIEWSОБЗОР ЛИТЕРАТУРЫReview ArticleMolecular markers of recurrence of basal cell skin cancerМолекулярно-генетические маркеры рецидивирования базальноклеточного рака кожиhttps://orcid.org/0000-0001-6132-56321149-2097SaytburkhanovRifat R.СайтбурхановРифат Рафаилевич
Russian Federation

Dermatovenereologist

врач-дерматовенеролог

rifat03@yandex.ruhttps://orcid.org/0000-0002-7625-05038771-4990KubanovAlexey A.КубановАлексей Алексеевич
Russian Federation

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

д.м.н., профессор, академик РАН

alex@cnikvi.ruhttps://orcid.org/0000-0003-3662-99548721-9424KondrakhinaIrina N.КондрахинаИрина Никифоровна
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

kondrakhina77@gmail.comhttps://orcid.org/0000-0003-4169-41287634-5521PlakhovaXenia I.ПлаховаКсения Ильинична
Russian Federation

MD, Dr. Sci. (Med.)

д.м.н.

plahova@cnikvi.ruState Research Center of Dermatovenereology and CosmetologyГосударственный научный центр дерматовенерологии и косметологии221120222701202398639472508202217112022Copyright ©; 2023, Saytburkhanov R.R., Kubanov A.A., Kondrakhina I.N., Plakhova X.I.Copyright ©; 2023, Сайтбурханов Р.Р., Кубанов А.А., Кондрахина И.Н., Плахова К.И.2023Saytburkhanov R.R., Kubanov A.A., Kondrakhina I.N., Plakhova X.I.Сайтбурханов Р.Р., Кубанов А.А., Кондрахина И.Н., Плахова К.И.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/1358

Basal cell carcinoma is the most common malignant neoplasm, andits incidence has been rapidly increasing worldwide. This malignancy is a serious public health problem that can lead to disability and severe aesthetic damage.

The results of the analysis of gene expression and proteomic profiling of tumor cells and the tumor microenvironment indicate that certain molecules involved in the pathogenetic pathways of basal cell skin cancer may represent new prognostic biomarkers or serve as the basis for their development.

The purpose of this review is to summarize information on known genes, proteins, and enzymes that can be used to diagnose, monitor therapy, and predict the course of basal cell skin cancer.

The PubMed, MedLine, Web of Science and RSCI databases were used to search for the necessary literature.

Базальноклеточная карцинома является наиболее распространенным злокачественным новообразованием, и в последние десятилетия заболеваемость им быстро растет во всем мире. Это злокачественное новообразование является серьезной проблемой общественного здравоохранения, которая может приводить к инвалидности и серьезному эстетическому ущербу.

Результаты анализа экспрессии генов и протеомного профилирования опухолевых клеток и опухолевого микроокружения свидетельствуют о том, что определенные молекулы, участвующие в реализации патогенетических путей базальноклеточного рака кожи, могут представлять собой новые прогностические биомаркеры или служить основой для их разработки.

Цель данного обзора — обобщить информацию об известных генах, белках и ферментах, которую можно использовать для диагностики, мониторинга терапии и прогнозирования течения базальноклеточного рака кожи.

Для поиска необходимой литературы использованы базы данных PubMed, MedLine, Web of Science и РИНЦ.

basal cell carcinomarecurrencebiomarkerбазальноклеточная карциномарецидивированиебиомаркерыСайтбурханов Р.Р., Кубанов А.А., Кондрахина И.Н., Плахова К.И. Современное представление о патогенезе базальноклеточного рака кожи. Вестник дерматологии и венерологии. 2021;97(5):38–51 [Saytburkhanov RR, Kubanov AA, Kondrakhina IN, Plakhova KI. Modern understanding of the pathogenesis of basal cell skin cancer. Vestnik dermatologii i venerologii. 2021;97(5):38–51. (In Russ)] doi: 10.25208/vdv1277Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069–1080. doi: 10.1111/j.1365-2133.2012.10830.xHoorens I, Vossaert K, Ongenae K, Brochez L. Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening. Br J Dermatol 2016;174(6):1258–1265. doi: 10.1111/bjd.14477Verkouteren J, Ramdas K, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol 2017;177(2):359–372. doi: 10.1111/bjd.15321Longo C, Lallas A, Kyrgidis A, Rabinovitz H, Moscarella E, Ciardo S, et al. Classifying distinct basal cell carcinoma subtype by means of dermatoscopy and reflectance confocal microscopy. J Am Acad Dermatol. 2014;71(4):716–724. doi: 10.1016/j.jaad.2014.04.067Ghita MA, Caruntu C, Rosca AE, Kaleshi H, Caruntu A, Moraru L, et al. Reflectance confocal microscopy and dermoscopy for in vivo, non-invasive skin imaging of superficial basal cell carcinoma. Oncol Lett. 2016;11(5):3019–3024. doi: 10.3892/ol.2016.4354Morgan FC, Ruiz ES, Karia PS, Besaw RJ, Neel VA, Schmults CD. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter. J Am Acad Dermatol. 2020;83(3):832–838. doi: 10.1016/j.jaad.2019.09.075Snow SN, Sahl W, Lo JS, Mohs FE, Warner T, Dekkinga JA, et al. Metastatic basal cell carcinoma. Report of five cases. Cancer. 1994;73(2):328–335. doi: 10.1002/1097-0142(19940115)73:2<328::aid-cncr2820730216>3.0.co;2-uКубанов А.А., Сайтбурханов Р.Р., Плахова К.И., Кондрахина И.Н. Возможности нехирургических методов лечения базальноклеточного рака кожи. Вестник дерматологии и венерологии. 2021;97(6):20–32 [Kubanov AA, Saytburkhanov RR, Plakhova KI, Kondrakhina IN. Non-surgical treatments for basal cell skin cancer. Vestnik dermatologii i venerologii. 2021;97(6):20–32. (In Russ)] doi: 10.25208/vdv1294Vornicescu C, Șenilă SC, Bejinariu NI, Vesa ȘC, Boșca AB, Chirilă DN, et al. Predictive factors for the recurrence of surgically excised basal cell carcinomas: A retrospective clinical and immunopathological pilot study. Exp Ther Med. 2021;22(5):1336. doi: 10.3892/etm.2021.10771Asplund A, Björklund MG, Sundquist C, Strömberg S, Edlund K, Ostman A, et al. Expression profiling of microdissected cell populations selected from basal cells in normal epidermis and basal cell carcinoma. Br J Dermatol. 2008;158(3):527–538. doi: 10.1111/j.1365-2133.2007.08418.xSallam RM. Proteomics in cancer biomarkers discovery: challenges and applications. Dis Markers. 2015:2015:321370. doi: 10.1155/2015/321370Bulman A, Neagu M, Constantin C. Immunomics in Skin Cancer — Improvement in Diagnosis, Prognosis and Therapy Monitoring. Curr Proteomics. 2013;10(3):202–217. doi: 10.2174/1570164611310030003El-Khalawany MA, Abou-Bakr AA. Role of cyclooxygenase-2, ezrin and matrix metalloproteinase-9 as predictive markers for recurrence of basal cell carcinoma. J Cancer Res Ther. 2013;9(4):613–617. doi: 10.4103/0973-1482.126456Telliez A, Furman C, Pommery N, Hénichart JP. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity. Anticancer Аgent Med Chem. 2006;6(3):187–208. doi: 10.2174/187152006776930891Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res. 2005;11(5):1999–2007. doi: 10.1158/1078-0432.CCR-04-1877Tjiu JW, Liao YH, Lin SJ, Huang YL, Tsai WL, Chu CY, et al. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol. 2006;126(5):1143–1151. doi: 10.1038/sj.jid.5700191Chen Y, Liu J. The prognostic roles of cyclooxygenase-2 for patients with basal cell carcinoma. Artif Cells Nanomed Biotechnol. 2019;47(1):3053–3057. doi: 10.1080/21691401.2019.1643731Park HR, Min SK, Min K, Jun SY, Seo J, Kim KH, et al. Differential expression of ezrin in epithelial skin tumors: cytoplasmic ezrinimmunoreactivity in squamous cell carcinoma. Int J Dermatol. 2010;49(1):48–52. doi: 10.1111/j.1365-4632.2009.04191.xSchlecht NF, Brandwein-Gensler M, Smith RV, Kawachi N, Broughel D, Lin J, et al. Cytoplasmic ezrin and moesin correlate with poor survival in head and neck squamous cell carcinoma. Head Neck Pathol. 2012;6(2);232–243. doi: 10.1007/s12105-011-0328-1Quintero-Fabián S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V, Lara-Riegos J, et al. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front Oncol. 2019;9:1370. doi: 10.3389/fonc.2019.01370Niland S, Riscanevo AX, Eble JA. Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression. Int J Mol Sci. 2021;23(1):146. doi: 10.3390/ijms23010146Vanjaka-Rogošić L, Puizina-Ivić N, Mirić L, Rogošić V, Kuzmić-Prusac I, Babić MS, et al. Matrix metalloproteinases and E-cadherin immunoreactivity in different basal cell carcinoma histological types. Acta Histochem. 2014;116(5):688–693. doi: 10.1016/j.acthis.2013.12.007Chu CY, Cha ST, Chang CC, Hsiao CH, Tan CT, Lu YC, et al. Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells. Oncogene. 2007;26(17):2491–2501. doi: 10.1038/sj.onc.1210040Tampa M, Georgescu SR, Mitran MI, Mitran CI, Matei C, Caruntu A, et al. Current Perspectives on the Role of Matrix Metalloproteinases in the Pathogenesis of Basal Cell Carcinoma. Biomolecules. 2021;11(6):903. doi: 10.3390/biom11060903Lei S, Zhang B, Huang L, Zheng Z, Xie S, Shen L, et al. SRSF1 promotes the inclusion of exon 3 of SRA1 and the invasion of hepatocellular carcinoma cells by interacting with exon 3 of SRA1pre-mRNA. Cell Death Discov. 2021;7(1):117. doi: 10.1038/s41420-021-00498-wBarbagallo D, Caponnetto A, Barbagallo C, Battaglia R, Mirabella F, Brex D, et al. The GAUGAA Motif Is Responsible for the Binding between circSMARCA5 and SRSF1 and Related Downstream Effects on Glioblastoma Multiforme Cell Migration and Angiogenic Potential. Int J Mol Sci. 2021;22(4):1678. doi: 10.3390/ijms22041678Broggi G, Lo Giudice A, Di Mauro M, Asmundo MG, Pricoco E, Piombino E, et al. SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study). Prostate. 2021;81(12):882–892. doi: 10.1002/pros.24185Law AM, Oliveri CV, Pacheco-Quinto X, Horenstein MG. Actin expression in purely nodular versus nodular-infiltrative basal cell carcinoma. J Cutan Pathol. 2003;30(4):232–236. doi: 10.1046/j.0303-6987.2003.054.xChristian MM, Moy RL, Wagner RF, Yen-Moore A. A correlation of alpha-smooth muscle actin and invasion in micronodular basal cell carcinoma. Dermatol Surg. 2001;27(5):441–445. doi: 10.1046/j.1524-4725.2001.00200.xIwulska K, Wyszyńska-Pawelec G, Zapała J, Kosowski B. Differences in actin expression between primary and recurrent facial basal cell carcinomas as a prognostic factor of local recurrence. Postepy Dermatol Alergol. 2021;38(3):490–497. doi: 10.5114/ada.2021.107935ShamsiMeymandi S, Dabiri S, ZeynadiniMeymand A, Iranpour M, Khalili M, Alijani S, et al. Evaluation of Immunohistochemical Findings and Clinical Features Associated with Local Aggressiveness in Basal Cell Carcinoma. Iran J Pathol. 2019;14(3):193–196. doi: 10.30699/ijp.2019.82907.1781